<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088400</url>
  </required_header>
  <id_info>
    <org_study_id>040244</org_study_id>
    <secondary_id>04-N-0244</secondary_id>
    <nct_id>NCT00088400</nct_id>
  </id_info>
  <brief_title>Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors</brief_title>
  <official_title>A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of intratumoral/interstitial therapy with TransMID compared to best&#xD;
      standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma&#xD;
      multiforme.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the safety of intratumoral/interstitial therapy with TransMID compared to best&#xD;
      standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma&#xD;
      multiforme.&#xD;
&#xD;
      To evaluate possible differences in efficacy and/or safety with TransMID associated with&#xD;
      differing degrees of transferrin receptor expression in tumor tissue and serum&#xD;
      anti-diphtheria toxin antibody titer levels.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen&#xD;
      considered to be best standard of care and consisting of either nitrosureas, platinum&#xD;
      compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) &amp; vincristine).&#xD;
      A planned interim analysis of the primary efficacy endpoint will be conducted after&#xD;
      approximately 50 percent of the required events have been observed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of intratumoral/interstitial therapy with TransMID compared to best&#xD;
      standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma&#xD;
      multiforme.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the safety of intratumoral/interstitial therapy with TransMID compared to best&#xD;
      standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma&#xD;
      multiforme.&#xD;
&#xD;
      To evaluate possible differences in efficacy and/or safety with TransMID associated with&#xD;
      differing degrees of transferrin receptor expression in tumor tissue and serum&#xD;
      anti-diphtheria toxin antibody titer levels.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen&#xD;
      considered to be best standard of care and consisting of either nitrosureas, platinum&#xD;
      compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) &amp; vincristine).&#xD;
      A planned interim analysis of the primary efficacy endpoint will be conducted after&#xD;
      approximately 50 percent of the required events have been observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Glioblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TransMID</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be included in the study if they meet all of the following criteria:&#xD;
&#xD;
          1. Male or female at least 18 years of age.&#xD;
&#xD;
          2. Histological results confirming GBM are available.&#xD;
&#xD;
          3. Progressive GBM (greater than or equal to 25 percent increase in contrast enhanced&#xD;
             tumor CSA compared to the nadir or smallest previous measured CSA) and/or recurrent&#xD;
             GBM after conventional treatment, including surgery (biopsy or debulking surgery)&#xD;
             and/or radiation therapy and/or chemotherapy.&#xD;
&#xD;
          4. Pre-study MRIs used to determine current progression and/or recurrence of GBM are&#xD;
             available to the Investigator and for independent confirmation of progression and/or&#xD;
             recurrence.&#xD;
&#xD;
          5. Patient is not considered a candidate for resection.&#xD;
&#xD;
          6. If female of child-bearing potential, a reliable method of contraception must be&#xD;
             combined with a negative pregnancy test before entering the study (female patients&#xD;
             must be willing to use contraception for 2 months after the last treatment with&#xD;
             TransMID (Trademark)). Male patients must be willing to use a barrier method of&#xD;
             contraception for up to 2 months after the last treatment with TransMID (Trademark)&#xD;
&#xD;
          7. Able and willing to follow instructions and comply with the protocol.&#xD;
&#xD;
          8. Provide written informed consent prior to participation in the study.&#xD;
&#xD;
          9. Karnofsky Performance Scale Score 70-100.&#xD;
&#xD;
         10. Tumor characteristics:&#xD;
&#xD;
             i) must be unifocal; and&#xD;
&#xD;
        ii) must be unilateral and supratentorial; and&#xD;
&#xD;
        iii) lesion must have a diameter (on contrast-enhanced MRI) greater than or equal to 1.0 cm&#xD;
        and less than or equal to 4.0 cm.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
          1. Anticipated life expectancy of less than 3 months.&#xD;
&#xD;
          2. Infratentorial or intraventricular tumors.&#xD;
&#xD;
          3. Presence of satellite tumors.&#xD;
&#xD;
          4. Chemotherapy within 30 days prior to study entry or nitrosureas or Mitomycin-C&#xD;
             containing therapy within 42 days prior to study entry.&#xD;
&#xD;
          5. Radiotherapy or stereotactic (gamma knife) radiosurgery within 90 days prior to study&#xD;
             entry.&#xD;
&#xD;
          6. Tumor surgery, tumor debulking or other neurosurgery within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          7. Previous administration of TransMID (Trademark)&#xD;
&#xD;
          8. Previous enrollment in this study.&#xD;
&#xD;
          9. Regional therapy including administration of biodegradable polymer wafers containing&#xD;
             carmustine within 90 days prior to study entry or brachytherapy within 12 calendar&#xD;
             months prior to study entry.&#xD;
&#xD;
         10. Significant liver function impairment-(total bilirubin greater than 2.0 mg/dl or 34.2&#xD;
             mircomol/L; AST or ALT greater than 3 times the upper limit of normal).&#xD;
&#xD;
         11. Significant renal impairment (serum creatinine greater than 1.7 mg/dL or 150&#xD;
             micromol/L).&#xD;
&#xD;
         12. Coagulopathy (prothrombin time [PT] or activated partial thromboplastin time [APTT]&#xD;
             greater than 1.5 times control).&#xD;
&#xD;
         13. Thrombocytopenia (platelet count less than 100 x 10(3)/micro-L or 100 x 10(9)/L).&#xD;
&#xD;
         14. Granulocytopenia (absolute neutrophil count (ANC), less than 1 x 10(3)/micro-L or 1.0&#xD;
             x 10(9)/L).&#xD;
&#xD;
         15. Severe acute infection.&#xD;
&#xD;
         16. Medical condition that is considered an unacceptable anesthetic risk.&#xD;
&#xD;
         17. Evidence of a mass effect on CT or MRI with more than a 5 mm midline shift and/or&#xD;
             nausea, vomiting, reduced level of consciousness or clinically significant&#xD;
             papilledema.&#xD;
&#xD;
         18. Nursing or pregnant females. A pregnancy test will be performed on all females who are&#xD;
             of child-bearing potential.&#xD;
&#xD;
         19. Use of any investigational product and/or participation in another clinical research&#xD;
             study within the last 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Neurological Disorders and Stroke (NINDS)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ameri A, Poisson M, Chen QM, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neurooncol. 1993 Jul;17(1):43-6.</citation>
    <PMID>8120571</PMID>
  </reference>
  <reference>
    <citation>Angelova-Gateva P. Iron transferrin receptors in rat and human cerebrum. Agressologie. 1980;21(1):27-30.</citation>
    <PMID>6263123</PMID>
  </reference>
  <reference>
    <citation>Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80.</citation>
    <PMID>8134351</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 23, 2004</study_first_submitted>
  <study_first_submitted_qc>July 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2004</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <keyword>Transferrin</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Convection</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Targeted Protein Toxin</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>GBM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

